Urinary anti-infectives

Definition and Pharmacological Purpose

Urinary anti-infectives are a specialized group of antimicrobial agents used to prevent and treat infections localized to the urinary tract, primarily urinary tract infections (UTIs). This class includes drugs with systemic antibiotic activity that concentrate in the urine and agents with local antiseptic activity within the urinary tract. Their pharmacokinetic profile ensures high urinary excretion and therapeutic levels in urine, making them particularly effective in managing lower urinary tract infections (cystitis) and, in some cases, upper urinary tract infections (pyelonephritis).

Some urinary anti-infectives are used prophylactically in patients with recurrent UTIs, catheter-associated infections, or anatomical abnormalities that predispose to infection. Others are reserved for treatment-resistant pathogens or multidrug-resistant bacteria.

---

Mechanism of Action

Urinary anti-infectives exert their therapeutic effects through various mechanisms:

1. Bactericidal action:

   • Inhibit cell wall synthesis (e.g., fosfomycin)

   • Inhibit DNA replication (e.g., fluoroquinolones)

   • Disrupt bacterial metabolism (e.g., nitrofurantoin)

2. Urinary antiseptic effect:

   • Compounds like methenamine decompose to formaldehyde in acidic urine, which exerts non-specific bactericidal effects.

3. Concentration-dependent killing:

   • Drugs such as ciprofloxacin show greater efficacy when peak urinary levels exceed the minimum inhibitory concentration (MIC).

---

Classification of Urinary Anti-Infectives

Urinary anti-infectives can be divided into:

1. Antibiotics with high urinary excretion

2. Urinary antiseptics (non-antibiotic)

3. Combination urinary preparations

---

Common Generic Names of Urinary Anti-Infectives

Class	Generic Names
Nitrofurans	Nitrofurantoin
Fosfomycin	Fosfomycin trometamol
Fluoroquinolones (UTI-specific)	Ciprofloxacin, Norfloxacin, Ofloxacin
Beta-lactams (selected agents)	Amoxicillin, Amoxicillin-clavulanate, Cefalexin, Cefuroxime
Sulfonamides	Trimethoprim, Trimethoprim–sulfamethoxazole (Co-trimoxazole)
Aminoglycosides (parenteral)	Gentamicin, Amikacin
Urinary antiseptics	Methenamine hippurate, Methenamine mandelate
Quinolone derivatives (older)	Nalidixic acid (rarely used)
Other antibiotics (select use)	Pivmecillinam, Doxycycline, Ertapenem (resistant UTI cases)

Detailed Pharmacological Profiles

1. Nitrofurantoin

• Mechanism: Bacterial enzyme-mediated reduction → reactive intermediates damage DNA, ribosomes

• Spectrum: E. coli, Enterococcus, Staphylococcus saprophyticus

• Form: Oral capsules or macrocrystals

• Dose: 50–100 mg twice daily (prophylaxis) or 100 mg BID (treatment)

• Use: Acute uncomplicated cystitis; not effective in pyelonephritis

• Contraindications: Renal impairment (CrCl <30 mL/min), late pregnancy

• Adverse Effects: Pulmonary fibrosis (chronic use), nausea, hemolytic anemia in G6PD deficiency

2. Fosfomycin trometamol

• Mechanism: Inhibits bacterial cell wall synthesis by blocking MurA enzyme

• Spectrum: E. coli (including ESBL-producing strains), Enterococcus faecalis

• Form: Oral powder (single-dose packet)

• Dose: 3 g single oral dose for uncomplicated UTI

• Advantages: Long half-life in bladder; minimal systemic effects

• Limitations: Resistance in some Klebsiella, Proteus spp.

3. Trimethoprim and Trimethoprim–Sulfamethoxazole (TMP-SMX)

• Mechanism: Sequential inhibition of bacterial folate synthesis

• Form: Oral tablets or suspension

• Dose: TMP 100 mg BID or TMP-SMX 160/800 mg BID for 3–5 days

• Use: Cystitis, pyelonephritis, prophylaxis

• Cautions: Avoid in sulfa allergy; hyperkalemia risk

• Resistance: Increasing resistance among E. coli strains globally

4. Fluoroquinolones (e.g., Ciprofloxacin, Norfloxacin)

• Mechanism: Inhibit DNA gyrase and topoisomerase IV

• Spectrum: Broad gram-negative coverage; active against Pseudomonas (ciprofloxacin)

• Dose: Ciprofloxacin 250–500 mg BID for 3–7 days

• Use: Pyelonephritis, complicated UTIs, prostatitis

• Risks: Tendinopathy, CNS effects, QT prolongation; avoid in uncomplicated cystitis unless no alternatives

5. Beta-lactams (e.g., Amoxicillin, Cefalexin, Cefuroxime)

• Mechanism: Inhibit bacterial cell wall synthesis

• Use: Empiric therapy in pregnancy, mild cystitis

• Dose:

  • Amoxicillin: 500 mg TID

  • Cefalexin: 500 mg BID or QID

• Limitations: Less active against resistant E. coli

• Preferred in: Children, pregnancy

6. Aminoglycosides (e.g., Gentamicin, Amikacin)

• Mechanism: Inhibit 30S ribosomal subunit, causing misreading of mRNA

• Use: Severe or complicated UTIs (IV only)

• Risks: Nephrotoxicity, ototoxicity

• Monitoring: Serum drug levels, renal function

7. Methenamine (Methenamine Hippurate, Methenamine Mandelate)

• Mechanism: Converts to formaldehyde in acidic urine (pH <5.5) → non-specific bactericidal action

• Form: Oral tablets

• Use: Chronic UTI prophylaxis

• Cautions: Ineffective in alkaline urine; not for active infections

• Often co-prescribed with: Ascorbic acid or hippuric acid to acidify urine

8. Pivmecillinam

• Mechanism: Penicillin derivative, inhibits cell wall synthesis

• Spectrum: E. coli, Klebsiella, Proteus

• Use: First-line in Nordic countries for uncomplicated UTIs

• Form: Oral

• Advantage: Low resistance rates

---

Formulations

• Oral (tablets, capsules, powders): Nitrofurantoin, TMP-SMX, Fosfomycin, Beta-lactams

• Parenteral (IV/IM): Aminoglycosides, cephalosporins, carbapenems

• Local urinary antiseptics: Methenamine

---

Clinical Considerations and Resistance

• Resistance to fluoroquinolones and TMP-SMX is rising globally due to overuse.

• Local antibiogram data should guide empirical treatment choices.

• Short-course therapies (e.g., 3-day nitrofurantoin or fosfomycin) are effective and help reduce resistance development.

• Methenamine is used only for prevention, not treatment, of UTIs.

---

Adverse Effects Overview

Drug	Common Adverse Effects
Nitrofurantoin	Nausea, pulmonary toxicity, hepatotoxicity
Fosfomycin	Diarrhea, headache, vaginitis
TMP-SMX	Rash, hyperkalemia, Stevens-Johnson syndrome (rare)
Fluoroquinolones	Tendon rupture, neuropathy, QT prolongation
Beta-lactams	Allergy, rash, GI upset
Methenamine	Bladder irritation, GI discomfort (rare)
Aminoglycosides	Renal toxicity, ototoxicity (requires drug monitoring)

Contraindications

• Nitrofurantoin: Renal impairment (CrCl <30 mL/min), term pregnancy

• TMP-SMX: Sulfa allergy, pregnancy (especially third trimester)

• Fluoroquinolones: Avoid in children, pregnancy unless absolutely necessary

• Methenamine: Not effective in alkaline urine; avoid in hepatic insufficiency

• Pivmecillinam: Hypersensitivity to penicillins

---

Drug Interactions

Drug	Interacting Agents
TMP-SMX	Warfarin (↑ INR), ACE inhibitors, ARBs (↑ K+)
Nitrofurantoin	Antacids (↓ absorption), probenecid (↑ toxicity risk)
Fluoroquinolones	Antacids, dairy (↓ absorption), QT-prolonging drugs
Methenamine	Sulfonamides (risk of crystalluria), urinary alkalinizers

Clinical Guidelines and First-Line Recommendations

According to guidelines by IDSA (Infectious Diseases Society of America) and NICE (UK):

• First-line agents for uncomplicated cystitis:

  • Nitrofurantoin (5 days)

  • Fosfomycin (single dose)

  • TMP-SMX (if resistance <20%)

• Second-line or alternatives:

  • Beta-lactams (amoxicillin, cefalexin)

  • Fluoroquinolones (if complications suspected)

---

Monitoring Parameters

• Symptom resolution: within 48–72 hours

• Urinalysis and culture: if infection recurs or fails to resolve

• Renal function tests: with nitrofurantoin, aminoglycosides

• Serum potassium: with TMP-SMX, especially in elderly or those on ACE inhibitors